Therapeutic variant alpha-2-macroglobulin compositions
US10400028B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 20, 2015 |
| Grant date | Sep 3, 2019 |
| Priority date | — |
| Expiry date | Nov 20, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A2M polypeptide compositions containing a non-natural bait region are disclosed. Methods of producing wild-type and variant A2M polypeptides and polynucleotides containing a non-natural bait region are also disclosed. The bait regions of the variant A2M polypeptides demonstrate enhanced protease inhibitory characteristics compared to wild-type A2M. Variant A2M polypeptides that demonstrate longer half-lives upon administration to an organism compared to wild-type A2M are disclosed. The A2M compositions are useful in treating a number of diseases and conditions including inflammation, chronic wounds, and diseases with a pathology associated with proteases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.